| Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study. | |
| | |
MedLine Citation:
|
PMID: 16968588 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tight blood pressure (BP) control is required to reduce cardiovascular morbidity and mortality. OBJECTIVE: To evaluate the efficacy and tolerability of the first line combination perindopril/indapamide in hypertension in daily practice. DESIGN AND METHODS: In this prospective, open-label, observational trial, 1892 general practitioners in Germany recruited patients with hypertension (n = 8023; mean age 59.6 years, 48.1% males, body mass index 27.6 kg/m2, systolic BP >or= 140 mmHg and/or diastolic BP >or= 90 mmHg) between October 2002 and December 2004. Patients received perindopril 2 mg/indapamide 0.625 mg for 12 weeks. BP measured in the general practice setting, safety, and tolerability were evaluated after 4 and 12 weeks. RESULTS: At baseline, most patients had moderate to severe hypertension (78%); initial BP was 164.6/95.8 mmHg. At inclusion, 38% of the patients were newly diagnosed hypertensives (mean BP 166.1/97.2 mmHg) and 58% of patients had uncontrolled BP despite preexisting antihypertensive treatment (163.5/94.9 mmHg). Previous treatment consisted of beta-blockers (49.5%), ACE inhibitors (36.4%), calcium-antagonists (29.3%), diuretics (28.8%), AT-I receptor antagonists (7.1%), and other treatments (8.1%). In the entire study cohort, treatment with perindopril/indapamide significantly decreased systolic BP (27.9 mmHg), diastolic BP (13.7 mmHg), and pulse pressure (14.2 mmHg), compared with baseline (p < 0.0001); 96% of patients responded to treatment and in 50% of patients BP was normalized (< 140/90 mmHg). Treatment dose was doubled in 9.5% of patients. Similar results were found in various subgroup analyses (newly diagnosed patients, the elderly, and patients with isolated systolic hypertension, additional cardiovascular risk factors, associated diseases, or target organ damage). The most frequent adverse events (< 1% of patients) were dry cough and nausea. CONCLUSIONS: The open-label, observational study PRIMUS, extends the existing evidence that the first line combination treatment of hypertension with perindopril/indapamide is effective, safe, and well tolerated in a representative cross-section of patients with newly diagnosed or pretreated but uncontrolled hypertension in daily practice. |
| | |
Authors:
|
Heinrich Holzgreve; Teut Risler; Peter Trenkwalder |
Related Documents
:
|
2909918 - The rostral basilar artery syndrome: diagnosis, etiology, prognosis. 1221278 - Idiopathic orthostatic hypotension controlled with a monoamine oxidase inhibitor and 9-... 8633508 - Is portal hypertension due to liver cirrhosis a major factor in the development of port... 7555038 - The effect of age and liver disease on the pharmacokinetics of the calcium antagonist, ... 18834288 - A view from riggs: treatment resistance and patient authority--viii. standards of care ... 4014568 - Alkaline reflux gastritis and the effect of biliary diversion on gastric emptying of so... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Current medical research and opinion Volume: 22 ISSN: 0300-7995 ISO Abbreviation: Curr Med Res Opin Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-09-13 Completed Date: 2007-01-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 1849-58 Citation Subset: IM |
Affiliation:
|
Kardiologische Praxis, Munich, Germany. H.Holzgreve@t-online.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antihypertensive Agents / adverse effects, therapeutic use* Blood Pressure / drug effects Drug Therapy, Combination Female Humans Hypertension / drug therapy* Indapamide / adverse effects, therapeutic use* Male Middle Aged Perindopril / adverse effects, therapeutic use* Prospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 26807-65-8/Indapamide; 82834-16-0/Perindopril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulan...
Next Document: Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pai...